Autophagy is a tightly regulated lysosomal self-digestion process that can both promote and impede tumorigenesis. Here, we utilize a three-dimensional (3D) culture model to address how interactions between autophagy and the phosphatidylinositol 3-kinase(PI3K)/Akt/mammalian target of rapamycin pathway impact the malignant behavior of cells carrying a tumor-derived, activating mutation in PI3K (PI3K-H1047R). In this model, autophagy simultaneously mediates tumor-suppressive and -promoting functions within individual glandular structures. In 3D culture, constitutive PI3K activation overcomes proliferation arrest and promotes resistance to anoikis in the luminal space, resulting in aberrant structures with filled lumen. Inhibiting autophagy in PI3K-H1047R structures triggers luminal cell apoptosis, resulting in lumen clearance. At the same time, autophagy gene depletion strongly enhances PI3K-H1047R cell proliferation during 3D morphogenesis, revealing an unexpected role for autophagy in restricting proliferation driven by PI3K activation. Intriguingly, overexpression of the autophagy cargo receptor p62/SQSTM1 in PI3K-H1047R cells is sufficient to enhance cell proliferation, activate the extracellular signal-related kinase/mitogen-activated protein kinase pathway and to promote epidermal growth factor-independent proliferation in 3D culture. Overall, these results indicate that autophagy antagonizes specific aspects of oncogenic PI3K transformation, with the loss of autophagy promoting proliferation.
INTRODUCTION
Autophagy is an evolutionarily conserved lysosomal degradation process that serves as an important mechanism for protein turnover and organelle homeostasis. 1 Autophagy is activated in response to multiple stresses relevant for cancer progression, including nutrient starvation, hypoxia, the unfolded protein response (ER stress) and extracellular matrix (ECM) detachment as well as upon treatment with a wide spectrum of cytotoxic and targeted chemotherapeutic agents. 2 As autophagy commonly functions as a survival and fitness mechanism in response to these diverse stresses, significant interest has emerged in inhibiting autophagy as a therapeutic strategy to kill or prevent the expansion of tumor cells. Notably, the lysosomal inhibitor hydroxychloroquine (HCQ), which inhibits the final maturation steps during autophagy, has gained special attention as an anticancer agent because of its long history of use as an antimalarial agent and in diseases such as rheumatoid arthritis; as a result, multiple clinical trials using HCQ as a sensitizing agent in combination with standard cancer therapies are under evaluation in different cancers. 3 Despite this enthusiasm for autophagy inhibition as a potential anticancer strategy, one cannot ignore genetic evidence supporting that autophagy can exert important tumor-suppressor functions. The ability of autophagy to prevent tumorigenesis was initially broached through studies of Beclin1/autophagy gene (ATG)6, which is allelically deleted in a large number of human breast, ovarian and prostate cancers. 4 Moreover, mice heterozygous for beclin1 show increased rates of spontaneous tumor development. 5, 6 More recently, mice with systemic mosaic deletion of atg5 and liver-specific atg7 À / À mice were found to develop hyperproliferative liver adenomas, further corroborating a genetic role for autophagy as a suppressor of spontaneous tumorigenesis. 7, 8 In addition, studies demonstrate that autophagy serves as an important mechanism for tumor suppression; defects in autophagy lead to activation of DNA damage responses, genomic instability and gene amplification. 9, 10 Importantly, ATG deficiency elicits high levels of tumor cell proliferation in these animal models, suggesting that autophagy has an important role in proliferative suppression in vivo. However, the exact mechanisms through which ATG deficiency causes an increase in cell proliferation remain unclear. Furthermore, it remains uncertain whether autophagy similarly augments cell proliferation downstream of oncogene activation. Here, utilizing a three-dimensional (3D) culture system, we interrogate how autophagy deficiency modulates oncogenic phosphatidylinositol 3-kinase (PI3K)-mediated transformation of mammary epithelial cells.
The aberrant activation of the PI3K/Akt/mammalian target of rapamycin (mTOR) signaling pathway is commonly observed in many cancers; the class I PI3K has a central role in cell growth, proliferation, differentiation and metabolism. PIK3CA, which encodes the p110a catalytic subunit of class I PI3K, is frequently mutated in cancers. In breast cancer, 425% of tumors harbor somatic mutations in PIK3CA, and commonly involve a hotspot mutation in the C-terminal kinase domain (H1047R). 11 Cells expressing mutant PIK3CA H1047R exhibit increased AKT and mTOR activity and have several phenotypic changes associated with oncogenic transformation, including adhesion-and growth factor-independent proliferation, protection from anoikis and abnormal morphogenesis in 3D culture. 12, 13 The aforementioned studies motivated us to scrutinize how autophagy impacts the growth and morphogenesis of mammary epithelial structures expressing PI3K-H1047R. We demonstrate that inhibiting autophagy sensitizes PI3K-H1047R cells occupying the 3D luminal space to undergo apoptosis. At the same time, we uncover an important role for autophagy in restricting cell proliferation driven by oncogenic PI3K activation. Accordingly, defective autophagy in PI3K-transformed epithelial cells results in enhanced levels of proliferation in 3D culture. Moreover, in response to rapamycin-mediated mTORC1 inhibition, we demonstrate that autophagy contributes to the suppression of proliferation in PI3K-transformed cells. Finally, we uncover that accumulation of the autophagy substrate p62/SQSTM1 is sufficient to activate the extracellular signal-related kinase/mitogen-activated protein kinase (ERK/MAPK) pathway and to enhance cell proliferation in oncogenic PI3K-expressing structures. Overall, these results point to important tumor suppressive functions for autophagy in the context of oncogenic PI3K activation, with the loss of autophagy promoting proliferation in 3D organotypic culture.
RESULTS
Autophagy inhibition concomitantly enhances luminal apoptosis and proliferation during 3D morphogenesis driven by the oncogenic PIK3CA mutant H1047R We utilized an established 3D culture system using MCF10A, a non-transformed human mammary epithelial cell line, to investigate PI3K-H1047R-driven transformation in a tissue-relevant context.
14 MCF10A cells stably expressing empty vector (LNCX) or PI3K-H1047R were cultured on a reconstituted laminin-rich basement membrane. Consistent with previous work, 13, 15 MCF10A cells expressing LNCX formed hollow gland-like structures that underwent proliferative arrest, evidenced by the near complete absence of the proliferation marker Ki-67 following 15 days in 3D culture ( Figure 1a ). In contrast, over this timecourse, PI3K-H1047R-expressing cells formed larger acini, and over longer periods, multi-acinar clusters. Importantly, these structures exhibited increased numbers of Ki67-positive cells and prominent luminal filling, indicating the expression of PI3K-H1047R enabled cells to both escape from proliferative suppression in 3D culture as well as survive in the luminal space ( Figure 1a) .
Although previous studies suggest that activation of the PI3K pathway suppresses autophagy induction via activating mTOR, 16 we observed autophagosome formation (punctate GFP-LC3) in acini derived from both LNCX and PI3K-H1047R cells stably expressing a GFP-LC3 reporter (Figure 1b) . To corroborate this result, we assessed the induction of autophagy in response to ECM detachment. MCF10A cells expressing LNCX or PI3K-H1047R were grown attached (Att) or in suspension (Sus) for 24 h, upon which autophagy was assessed by monitoring the turnover of lipidated LC3/ATG8 (LC3-II) in the absence versus presence of the lysosomal cathepsin inhibitors, E64D and pepstatin A (E/P). 17 LNCX and PI3K-H1047R cells showed equivalent levels of autophagic flux following ECM detachment (Supplementary Figure 1A) . Furthermore, both LNCX and PI3K-H1047R cells stably expressing a GFP-LC3 reporter both showed a robust induction of autophagosomes upon ECM detachment (Supplementary Figure 1A) . Overall, these results indicate that the activation of the PI3K/Akt pathway does not suppress autophagy during 3D morphogenesis or in response to ECM detachment.
Our recent work demonstrated that autophagy functions as a survival pathway during luminal clearance in MCF10A acini grown in 3D culture. 18 To assess whether autophagy contributes to the luminal filling in PI3K-H1047R-expressing 3D structures, we transduced these cells with lentiviral constructs encoding short hairpin RNAs against ATG7 (shATG7) or ATG12 (shATG12), two essential ATGs. Stable ATG7 or ATG12 knockdown reduced LC3-II turnover (autophagic flux) during ECM detachment to B50% of controls (Supplementary Figure 1B) . Notably, ATG knockdown did not alter PI3K activity as assessed by serine 473 phosphorylation of the downstream effector, AKT (Supplementary Figure 1C) . Although ATG depletion did not significantly alter the overall morphology of PI3K-H1047R structures (Figure 1c) , these knockdowns resulted in up to a threefold increase in luminal apoptosis, evidenced by increased cleaved caspase-3-positive cells occupying the luminal space of day 7 structures (Figure 1d ). Importantly, these apoptotic cells lacked direct contact with the underlying basement membrane, indicating that they were dying via anoikis. 15 By day 15, the majority of shATG7 and shATG12 cell-derived acini exhibited luminal space clearance, in contrast to PI3K-H1047R shNT acini, which exhibited filled lumen (Figure 1e ). In addition, in soft agar transformation assays, adhesion-independent growth of PI3K-H1047R cells decreased by 61.8% and 75.8% upon ATG7 or ATG12 depletion, respectively (Supplementary Figure 1D) . Overall, these results demonstrate that autophagy is critical for the survival of PI3K-H1047R-expressing cells lacking ECM contact.
Although ATG-depleted acini exhibited enhanced luminal apoptosis, the total number of cells recovered from day 7 3D cultures of shATG7 and shATG12 cells was only slightly decreased compared with controls ( Supplementary Figure 2A) . Given these modest effects, we assessed whether ATG depletion concomitantly affected cell proliferation driven by oncogenic PI3K in 3D culture. Both PI3K-H1047R-shATG7 and shATG12 structures exhibited an almost twofold increase in Ki67 activity compared with control cells. This hyperproliferative phenotype in ATG-depleted structures was observed in both early (day 7) and late (day 15) stages of 3D culture (Figure 1f ). These results were corroborated using a second proliferation marker, phosphorylated Rb (pRb-S780) (Supplementary Figure 2B) . Increased proliferation was not observed in ATG-depleted cells cultured in monolayer (Supplementary Figure 2C) , indicating that autophagy inhibition does not enhance proliferative capacity of PI3K-H1047R cells grown in 2D conditions; rather, it enhances the ability of these cells to escape proliferative suppression in 3D culture.
Autophagy is not essential for the growth-suppressive effects of rapamycin in PI3K-H1047R 3D cultures Previous work indicates that mTORC1 activity is required for the phenotypes mediated by PI3K/Akt pathway activation in 3D culture; the allosteric mTORC1 inhibitor rapamycin suppresses the development of large, distorted structures mediated by PI3K-H1047R. 13 As rapamycin-mediated inhibition of mTORC1 induces autophagy in cells, 19 we assessed the functional impact of autophagy inhibition on rapamycin-mediated growth suppression. Rapamycin treatment reduced acinar size of the PI3K-H1047R-derived cells by 43.5% (Figure 2a ). In contrast, rapamycin elicited a 26.9% and 35% reduction in structure size of PI3K-H1047R-shATG7 and shATG12 cells, respectively. Although these results suggest that autophagy may partly contribute to the reduction of PI3K-H1047R structure size during rapamycin treatment, autophagy is not essential for rapamycin-mediated growth suppression in this model. Furthermore, we observed significantly increased Ki67 activity in ATG knockdown cells treated with rapamycin, indicating that autophagy continues to restrict proliferation in response to rapamycin treatment (Figure 2b ).
To further corroborate these results, we examined whether autophagy deficiency similarly affected 3D morphogenesis of cells expressing oncogenic AKT. In MCF10A cells expressing a conditionally activated variant of AKT (ER-AKT), treatment of cells with 4-hydroxytamoxifen activates AKT and induces proliferation in 3D culture, resulting in large, misshapen structures. Similar to PI3K-H1047R, rapamycin-mediated mTORC1 inhibition reverts these phenotypes associated with AKT activation. 20 In ER-AKT cells, ATG7 knockdown did not significantly affect AKT activation induced by 4-hydroxytamoxifen treatment (Supplementary Figure 3A) ; in the presence of 4-hydroxytamoxifen, shATG7 cells formed larger, distorted acini in 3D culture resembling nontargeting controls (ER-AKT-shNT) (Supplementary Figure 3B) . Upon rapamycin treatment, ER-AKT-shNT cells formed small, spherical acini that resembled ethanol (ETOH)-treated controls; ER-AKT cells with ATG7 depletion also exhibited a significant reduction in structure size in response to rapamycin (Supplementary Figure 3B) . However, while rapamycin treatment decreased Ki67 activity in AKT-activated structures, knockdown of either ATG7 or ATG5, another essential ATG, enabled higher rates of proliferation in ER-AKT cells in the presence of rapamycin (Supplementary Figure 3C) . Overall, these results corroborate that autophagy continues to restrict oncogenic PI3K/Akt-driven proliferation in response to rapamycin-mediated mTORC1 inhibition.
CQ-mediated lysosomal inhibition enhances ERK/MAPK pathway activation and induces the proliferative outgrowth of PI3K-H1047R subpopulations in 3D culture The anti-malarial CQ is a weak base that can neutralize acidic intracellular compartments such as late endosomes and lysosomes. 21 Both CQ and its derivative, HCQ, are currently being used in numerous human cancer clinical trials as autophagy inhibitors to block the late stages of autophagy. 22 We therefore evaluated how CQ treatment impacted PI3K-H1047R-driven morphogenesis. Based on the accumulation of LC3-II, we established that a range of concentrations of CQ were able to effectively inhibit autophagic degradation with maximal inhibition obtained at doses of 20 mM or higher (Supplementary Figure 4A) . In monolayer culture, CQ suppressed PI3K-H1047R cell proliferation in a dose-dependent manner that became even more pronounced when combined with rapamycin ( Figure 3a) . In 3D culture, treating cells with 20 mM CQ alone or in combination with rapamycin fully suppressed the outgrowth of PI3K-H1047R acini (Figure 3b ). In contrast, upon treatment with a lower dose of 10 mM, a heterogeneous cell population was observed. Although certain CQ-treated individual cells were unable to grow out in these cultures, a significant subpopulation of cells exhibited enhanced proliferative capacity compared with untreated controls, resulting in the formation of large structures that were highly Ki67-positive (Figures 3b and c) . Notably, numerous hyperproliferative outgrowths were also observed in cultures concomitantly treated with CQ and rapamycin, although the size of the outgrowths was reduced in comparison with cultures treated with CQ alone (Figure 3b) ; furthermore, structures treated with rapamycin plus 10 mM CQ exhibited higher Ki67 activity compared with those treated with rapamycin alone (Figure 3d ).
As the ERK/MAPK pathway is an important factor of proliferation in MCF10A 3D culture, 15, 23 we further interrogated whether CQ treatment impacted activation of the ERK/MAPK pathway. Fluorescence-activated cell sorting analysis revealed that cells treated with low-dose CQ exhibited enhanced ERK activation, as delineated by increased phospho-ERK1/2 (pERK) staining (Figure 4a ). We then tested whether the outgrowth of PI3K-H1047R cells in the presence of low-dose CQ is sensitive to ERK/ MAPK pathway inhibition using U0126, a highly selective and potent inhibitor of the ERK/MAPK signaling cascade via inhibition of the immediate upstream activators, MAP kinase kinase 1 and 2 (also known as MAPK/ERK kinase1/2). We treated 3D cultures with U0126 alone or in combination with low-dose CQ for 8 days. Treatment with U0126 alone was found to have modest effects on PI3K-H1047R structure size in 3D culture. Nevertheless, U0126 robustly suppressed the outgrowth of PI3K-H1047R cells in the presence of 10 mM CQ (Figure 4b) . Furthermore, staining for the proliferation marker pRb-S780 revealed that ERK/MAPK inhibition markedly decreased cell proliferation in these structures (Figure 4c) . Together, these results indicate that although CQ can effectively inhibit autophagy over a range of concentrations, its ultimate outcome on 3D growth and proliferation driven by PI3K-H1047R is dose dependent; at lower doses, CQ treatment promotes the outgrowth of a highly proliferative PI3K-H1047R subpopulation, which appears to be at least partly arise due to the activation of the ERK/MAPK pathway in these cells.
p62/SQSTM1 cooperates with PI3K-H1047R to enhance cell proliferation in 3D culture p62/SQSTM1 is a signaling adaptor protein that is selectively degraded via autophagic pathways. 24 Genetic deletion of ATGs results in spontaneous tumor formation and p62 accumulation in tumor cells, 7, 8 while p62 overexpression enhances tumorigenicity of autophagy-deficient cells in vivo. 25 These studies support that p62 accumulation has an important role in the tumorigenesis mediated by autophagy deficiency. In this 3D culture system, PI3K-H1047R cells treated with CQ alone or in combination with rapamycin exhibited significantly increased p62 levels (Supplementary Figure 4B) , which motivated us to interrogate whether p62 accumulation is sufficient to enhance cell proliferation associated with autophagy deficiency in 3D culture. We stably expressed HA-tagged wild-type p62 (p62-WT) or a mutant p62 (p62-LC3-interacting region (LIR)) in control cells (LNCX) and PI3K-H1047R-expressing cells. The p62-LIR contains a mutation (W338A) within the LIR, rendering it resistant to degradation via autophagy. 26 As shown in Supplementary Figure 5A , WT p62 but not p62-LIR was degraded in response to nutrient starvation (Hank's balanced salt solution treatment) in both LNCX and PI3K-H1047R cells. In 3D culture, p62-WT or p62-LIR expression had minimal effects on acini size in LNCX cells (Supplementary Figure 5B) . In contrast, when co-expressed with PI3K-H1047R, p62-WT expression caused a 25% increase in average acini size; this phenotype was further enhanced in PI3K-H1047R cells expressing p62-LIR, which produced a 43% increase in average (Figure 5a ). In addition, we observed significantly increased Ki67 activity in p62-WT-and p62-LIR-expressing PI3K-H1047R acini (Figure 5b ). Similar to our results with ATG depletion, we did not observe enhanced cell proliferation in p62-overexpressing PI3K-H1047R cells grown in monolayer culture (Supplementary Figure 5C) ; rather, the proliferative phenotype was only observed in 3D culture conditions. Overall, these results indicate that while the accumulation of p62 alone is not sufficient to enhance growth and proliferation in WT (LNCX) MCF10A acini, it can enhance proliferation and growth capacity in cooperation with oncogenic PI3K activation in 3D culture.
Furthermore, we also detected a stronger pERK signal in PI3K-p62-LIR cells collected from day 7 3D cultures ( Figure 6a, left) . Flow cytometric quantification corroborated a 40% increase in pERK signal intensity in PI3K-p62-LIR cells harvested on day12 compared with controls (Figure 6a, right) . Treatment of PI3K-p62-LIR cells with U0126 significantly decreased structure size and cell proliferation compared with untreated cultures, indicating that the ERK/MAPK pathway activation is an important contributor to p62-LIR-induced hyperproliferation in PI3K-H1047R cells (Figures 6b and c) . As a result of these effects of p62 on ERK/ MAPK activation, we subsequently evaluated how p62 accumulation influenced proliferation in 3D cultures lacking epidermal growth factor (EGF). Whereas proliferation of WT MCF10A cells is strictly EGF-dependent, PI3K-H1047R-expressing cells exhibit lowlevel proliferation in the absence of exogenously provided EGF. 13 Consistent with previous results, PI3K-H1047R, but not vector control (LNCX) cells, formed small structures after 22 days of culture (Figure 7a, left) . The expression of p62-LIR significantly enhanced the EGF-independent growth of PI3K-H1047R cells in 3D culture (Figure 7a, right) . Whereas LNCX-p62-LIR cells showed extremely limited proliferation capacity in the absence of exogenous EGF, PI3K-H1047R-p62-LIR cultures contained multiple cell clusters that exhibited increased Ki67 activity compared with controls ( Figure 7b ). Furthermore, a stronger pERK signal was detected in PI3K-p62-LIR acini grown in the absence of EGF in comparison with PI3K-BABE controls (Figure 7c) . Overall, these results suggest that p62 accumulation cooperates with oncogenic PI3K to enhance cell proliferation in MCF10A 3D culture, both in the presence or absence of EGF; moreover, this proliferative phenotype correlates with enhanced activation of the ERK/MAPK pathway.
ATG depletion enhances the ERK/MAPK pathway activation in PI3K-H1047R structures Last, we assessed the effects of ATG depletion on the ERK/MAPK pathway activation in PI3K-H1047R cells in 3D culture. Fluorescence-activated cell sorting analysis revealed PI3K-shATG7 and -shATG12 cells exhibited increased pERK activity compared with control cells (Figure 8a ). U0126 treatment significantly decreased the structure size of ATG-depleted PI3K-H1047R cells; upon U0126 treatment, structure size was reduced by 9% in shNT cells, 25.2% in shATG7 and 26.1% in shATG12 cells (Figure 8b) . The ERK/MAPK pathway inhibition also decreased ATG depletion-mediated hyperproliferation of PI3K-H1047R cells (Figure 8c ). Taken together, these results support that the activation of the ERK/ MAPK pathway serves as one important mechanism by which autophagy deficiency enhances the proliferation of PI3K-H1047R cells in 3D culture.
DISCUSSION
Growing evidence reveals multiple context-dependent roles for autophagy in cancer. 3 Genetic studies reveal that autophagy promotes genome integrity and serves as a barrier to limit cancer initiation. However, in established tumors, autophagy functions as a survival and fitness mechanism that is critical for tumor progression and maintenance. 27 Here, we utilize a 3D epithelial culture model to demonstrate that in response to oncogenic PI3K activation, autophagy can simultaneously mediate both tumorsuppressive and -promoting functions within the same glandular Figure 6 . p62/SQSTM1-mediated proliferation of PI3K-H1047R cells in 3D culture is associated with activation of the ERK/MAPK pathway. (a) In 3D cultures of the indicated cell types grown in standard assay media, pERK levels were determined by immunoblotting of cell lysates (day 7) or flow cytometry (day 12). (b) Left: phase images of day 7 3D cultures treated with dimethyl sulfoxide or 10 mM U0126 as indicated. Bar, 100 mM. Right: acinar size distribution on day 7 of 3D culture. A total of 300 acini from three independent experiments were measured for each condition. Results represent mean ± s.e.m. ***Po0.001, Student's t-test. (c) Left: day 7 3D structures were fixed and immunostained with antibodies against pRb-S780 (green), laminin-5 (red) and 4 0 6-diamidino-2-phenyl indole (DAPI) counterstained (blue). Bar, 50 mM. Right: the percentage of pRb-S780-positive nuclei per acinus was quantified. For each cell type and condition, a total of 150 acini from three independent experiments were analyzed. Results represent the mean±s.e.m. *Po0.05, ***Po0.001, Student's t-test.
structure. We uncover that ATG depletion strongly enhances cell proliferation within PI3K-H1047R structures, suggesting that autophagy restricts the proliferation of oncogenic PI3K-expressing cells in 3D culture. At the same time, ATG knockdown results in increased luminal apoptosis and luminal space clearance, indicating that autophagy is crucial for the survival of oncogenic PI3K-expressing cells deprived of ECM contact. Importantly, we find that cell-ECM contact dictates the manifestation of these two phenotypes within these structures. Increased levels of proliferation are observed throughout the structure, both in detached cells occupying the lumen as well as in outer cells that directly contact the surrounding ECM. In contrast, the increase in apoptosis is restricted only to the centrally located cells deprived of ECM contact. These findings illustrate that although both tumor-suppressive and -promoting functions of autophagy may co-exist, the precise effect of autophagy inhibition on cell fate is ultimately determined by environmental constraints imposed on the oncogene-expressing cells.
Increased cell proliferation has been observed in several autophagy-deficient tissues in vivo. However, in monolayer cultures, autophagy inhibition often decreases or has no effect on cell proliferation in vitro. [28] [29] [30] Here, we demonstrate that the enhanced cell proliferation arising from autophagy deficiency, pharmacological lysosomal inhibition and p62 accumulation is only evident in 3D culture conditions; no such phenotypes are present in PI3K-H1047R cells grown in monolayer. We propose that the enhanced rates of proliferation resulting from defective autophagy only become manifest in more tissuerelevant settings, such as those provided in 3D culture models. Hence, 3D systems may serve as useful tools to dissect how autophagy impacts proliferation control and cell fate during oncogenic transformation. 31 Currently, multiple clinical trials using HCQ are in progress to evaluate whether autophagy inhibition is able to sensitize tumor cells to undergo death, either alone or in combination with anticancer therapy. At the same time, there is immense clinical interest in mTOR inhibition as a therapeutic strategy against tumors. 32 As mTOR serves as a key negative regulator of autophagy, an important question is whether autophagy contributes to the anticancer effects of pharmacological mTOR inhibitors, or alternatively, if this process promotes drug resistance in response to such agents. 33 Our results using rapamycinmediated allosteric mTORC1 inhibition in cells transformed by oncogenic PI3K (or Akt) support that autophagy continues to contribute to efficient proliferative suppression in 3D culture; however, autophagy is not critical for the ability of rapamycin to suppress the growth of PI3K-H1047R 3D structures. In addition, although the lysosomal inhibitor CQ is able to suppress the proliferation of PI3K-H1047R cells propagated in standard monolayer culture, we demonstrate that a subpopulation of hyperproliferative structures readily emerge in 3D culture conditions, especially when CQ is utilized at lower doses. As CQ and HCQ are currently being used in clinical trials as a treatment against a wide spectrum of cancers, our findings point to the importance of optimal dosage of these agents in clinical oncology settings.
Finally, we demonstrate that accumulation of the autophagy substrate and cargo receptor, p62/SQSTM1, is sufficient to enhance proliferation in PI3K-H1047R cells. Interestingly, our results indicate that p62 overexpression is not sufficient as an isolated insult to overcome 3D proliferative suppression, nor is it able to promote EGF-independent proliferation in 3D culture. These results broach the possibility that the ability of p62 to drive proliferation in autophagy-deficient cells may be significantly amplified in combination with additional oncogenic insults that activate the PI3K/Akt signaling axis.
As a adaptor protein, p62/SQSTM1 binds to proteins involved in several signaling pathways. 34 In this model, the expression of an autophagy-resistant form of p62 (p62-LIR) enhances the ERK/ MAPK pathway activation, which cooperates with oncogenic PI3K to promote cell proliferation. Similarly, both CQ-mediated autophagy inhibition and ATG depletion in PI3K-H1047R cells are able to promote ERK/MAPK activation in 3D culture. Furthermore, the MAPK/ERK kinase inhibitor U0126 attenuates the enhanced growth and proliferation observed upon autophagy inhibition or p62-LIR overexpression in 3D culture. Altogether, these data support that autophagy restricts proliferation in PI3K-H1047R cells at least partly via downregulation of the ERK/MAPK mitogenic pathway. However, it is important to recognize that despite this sensitivity of ATG-deficient and p62-LIR-expressing cells to MAPK/ERK kinase inhibition in 3D culture, the U0126-treated structures derived from these cells do remain significantly larger and more proliferative than U0126-treated control cells (Figures 6c and 8c) . These results broach the possibility that autophagy and p62/SQSTM1 direct additional pathways, such as the previously reported nuclear factor-kB and Nfr2 pathways, which contribute to their ability to suppress tumor cell growth and proliferation.
In summary, our data delineate diverse biological functions for autophagy during 3D morphogenesis driven by oncogenic PI3K. Importantly, autophagy inhibition promotes the apoptosis of oncogenic cells under duress, in this case, due to ECM deprivation. Nevertheless, inhibiting autophagy leads to enhanced cell proliferation and activation of the ERK/MAPK pathway in this 3D culture model. Currently, there is great interest in targeting autophagy as an anticancer strategy. Our study suggests that the potential untoward effects of autophagy inhibition on cell proliferation should be considered when applying autophagy inhibition as a clinical treatment against cancer.
MATERIALS AND METHODS
Cell lines and culture conditions MCF10A-derived cell lines were generated and cultured as described previously.
14 Stable pools were generated by selection with 2 mg/ml Puromycin or 300 mg/ml G418.
3D morphogenesis assays
3D culture of MCF10A-derived cell lines on Matrigel (BD Biosciences, San Jose, CA, USA) was performed as described previously.
14 Culture media was refreshed every 4 days, unless otherwise indicated. When indicated, the following reagents were added on day 1 of culture and refreshed every 4 days: 25 nM rapamycin (Rap EMD-Millipore, Billerica, MA, USA), 10 or 20 mM CQ diphosphate salt (Sigma-Aldrich, St Louis, MO, USA), 1 mM 4-Hydroxytamoxifen (Sigma-Aldrich). For proliferation assays, 10 mM U0126 (EMD-Millipore) was added on day 1, refreshed on day 4 and 24 h before analysis.
Antibodies
Commercial antibodies include: a-Ki67 (Invitrogen, Carlsbad, CA, USA), a-phospho-Akt (Ser473), a-AKT, anti-cleaved caspase-3, a-phospho-Rb (Ser780), a-phospho-p44/42 MAPK (Erk1/2)-Alexa Fluor 488 Conjugate, a-phospho-p44/42 MAPK (Erk1/2)-Alexa Fluor 647 Conjugate, a-ATG12 (Cell Signaling Technology, Danvers, MA, USA), a-pERK (Biosource, Camarillo, CA, USA), a-ATG7 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), a-laminin 5 (EMD Millipore), a-p62 (Progen Biotechnik, Heidelberg, Germany), a-HA (HA.11, Covance, Princeton, NJ, USA), a-a-tubulin (SigmaAldrich) and anti-LC3 antibody has been described previously. 18 
Retroviral vectors and virus production
The retroviral vector pLNCX-neo containing PI3K-H1047R was kindly provided by Dr W Weiss. pBABEpuro GFP-LC3 and pWZLneo ER-Akt have been described previously. 20, 30 Human p62 cDNA was a kind gift from Dr T Johansen. To generate pBABEpuro-p62-WT, p62 was amplified and cloned into a pBABEpuro vector containing a 5' HA-tag. To generate pBABEpuro-p62-LIR, a point mutation at position 338 (p62 W338A ) in pBABEpuro-p62-WT was introduced using the QuickChange XL SiteDirected Mutagenesis kit (Stratagene, La Jolla, CA, USA). For retroviral transduction, VSV-G-pseudotyped retroviruses were generated, and cells were infected and selected as described previously. 14 Short hairpin RNA and siRNA pLKO.1 lentiviral expression vectors containing short hairpin RNAs against ATG7 and ATG12 were purchased from Sigma (Mission short hairpin RNA). The target sequence for hairpins directed against human ATG7 (NM_006395) is: shATG7 (TRCN0000007584): 5 0 -GCCTGCTGAGGAGCTCTC CA-3 0 ; directed against human ATG12 (NM_004707) is: shATG12 (TRCN0000007394): 5 0 -TGGAACTCTCTATGAGTGTTT-3 0 . For siRNA-mediated knockdown of ATGs, siGenome SMARTpool siRNAs against human ATG7 (M-020112-01) and human ATG5 (M-004374-04) were purchased from Dharmacon RNA Technologies, Lafayette, CO, USA and cells were transfected as described previously. 18 Phase and immunofluorescence image acquisition and analysis Phase images of 3D culture were acquired on an Axiovert 200 microscope (Carl Zeiss, Thornwood, NY, USA) equipped with a Spot RT camera (Diagnostic Instruments, Sterling Heights, MI, USA). For confocal analyses, 3D cultures were fixed and stained as described previously.
14 Images were acquired using a C1Si confocal laser-scanning microscope (Nikon, Melville, NY, USA) and analyzed using the EZ-C1 software (v3.20, Nikon). Acini area was measured using the MetaMorph software (v6.0, GE Healthcare, Little Chalfont, UK).
Flow cytometry
Cells were harvested from 3D cultures and fixed in 4% paraformaldehyde followed by resuspension in cold 90% methanol for 30 min on ice. Cells were then subject to antibody staining according to the manufacturer's protocol. For flow cytometric detection of pERK activity, assay media for 3D cultures was not replenished before harvest.
